Abstract
Drug Delivery Doxorubicin-loaded DPPG2-TSL nanocarriers represent a novel temperature-dependent drug delivery system. Heating the tumor tissue to 41°C leads to its intravascular doxorubicin release, which then penetrates the tumor tissue and results in significantly higher intratumoral doxorubicin concentrations. This improves local efficacy while reducing systemic side effects. The described nanocarriers have great potential for the treatment of locally advanced tumors in humans. More details can be found in article number 2000089 by Lars H. Lindner and co-workers.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
